Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

LSD Derivative DT120 Earns FDA Breakthrough Status for MDD

11 September 2026 · By · Wire by Fusion42

Published

11 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at psychiatryadvisor.com →

◆ Verified

Fusion42 · 11 September 2026 · Fusion42 review

DT120, an LSD derivative, has received FDA Breakthrough Therapy designation for major depressive disorder (MDD) based on positive phase 3 trial results showing significant and durable improvement in depression symptoms.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 8 Sep 2026 and 11 Sep 2026.

◆ ◆ The Wire takeaway

You now face a faster approval path for psychedelic-derived treatments in depression. This clears a way for rapid market entry and heightens pressure to prepare regulatory and commercial strategies for novel mental health drugs.

◆ Coverage

2 sources · first reported 8 Sep 2026 · latest 11 Sep 2026

◆ Related on Wire

◆ Topics

BiotechFDAbreakthrough-therapymajor-depressive-disorderpsychedelic-medicineclinical-trial